The UK biotech company has chosen to list on its home market rather than go to the Nasdaq in New York, the traditional listing venue for companies in the industry
Oxford Nanopore seeks valuation of up to £3.8bn
Most Popular
The UK biotech company has chosen to list on its home market rather than go to the Nasdaq in New York, the traditional listing venue for companies in the industry